|
|
 |
|
Viewing report
|
|
|
|
The War On Cancer - 2nd Edition
Centient Consulting, Inc, Sep 2005, Pages: 20
This report examines the 25 year battle against one of the world's deadliest diseases, cancer, and the companies and technologies poised to change the course of the war. The science and mechanisms of action behind newer blockbuster drugs like Gleevec, Avastin and Tarceva are reviewed, and new research holding significant promise from 24 public and private companies including AstraZeneca, Celgene, Genentech, Imclone, Merck and others are identified. The potential impact of the pending paradigm shift to personalized medicine is also analyzed.
Reasons to Purchase
- Understand the technologies holding the greatest promise of treating or even curing cancer including anti-angiogenesis, tyrosine kinase inhibitors and epidermal growth factor receptors (EGFRs)
- Identify the companies leveraging these technologies and the drugs in development and trials
- Examine the scientific and regulatory hurdles facing these companies in their quest to bring novel drugs to market
- Identify potential collaborative partners and/or investment opportunities
Target Audience
- Marketing and senior execs/managers wishing to understand the changing landscape of cancer research
- Research and development execs/managers wanting to know the current state-of-the-art
- Venture capitalists and fund managers analyzing investments in cancer therapeutics
- Analysts and journalists researching cancer drug development
- Physicians and patients seeking information on new cancer drugs and clinical trials
- Others seeking to understand the potential promise of cancer research
Report Highlights
The imagery of battle is very powerful. It rouses our spirits, clarifies our goals, and gives us a deep sense of purpose. We like to think of ourselves as warriors engaged in epic battles with dark forces. America's war on cancer began when President Nixon signed the National Cancer Act into law on Dec. 23, 1971. Now, 35 years and billions of dollars later, science has finally positioned us to win some strategic battles in the war on this deadly disease.
We now have many areas where we have a good understanding of the science of cancer and therefore where to focus to intervene to disrupt tumor growth. The report explores three of the more interesting avenues for attack - anti-angiogenesis, tyrosine kinase inhibitors, and epidermal growth factor receptors (EGFRs) - the companies pursuing these technologies and the drugs in development.
Clinical trials can significantly complicate the process of bringing a cancer drug to market. Efficacy is measured differently in Phase II and Phase III studies – tumor shrinkage vs. extended survival. The report explore how this can slow or even prevent an apparently effective from reaching the market, as was the case with AstraZeneca's lung cancer drug, Iressa.
The report also explores the coming paradigm shift in personalized medicine, and how it can improve the drug discovery and development process, and ultimately, patient care.
This is the 2nd edition of Inc.'s most popular and most quoted report, 'The War on Cancer.'
|
|
|
|
